Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMedOpen access

The fibro-adipogenic progenitor APOD+DCN+LUM+ cell population in aggressive carcinomas.

Cai L., Kolonin MG., Anastassiou D.

Narrative Review, published in Cancer Metastasis Rev (2024) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Cancer Metastasis Rev (2024)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
38466528
PMCID
PMC11300568
DOI
10.1007/s10555-024-10181-y
Citations
14

Abstract (original English)

We identified a progenitor cell population highly enriched in samples from invasive and chemo-resistant carcinomas, characterized by a well-defined multigene signature including APOD, DCN, and LUM. This cell population has previously been labeled as consisting of inflammatory cancer-associated fibroblasts (iCAFs). The same signature characterizes naturally occurring fibro-adipogenic progenitors (FAPs) as well as stromal cells abundant in normal adipose tissue. Our analysis of human gene expression databases provides evidence that adipose stromal cells (ASCs) are recruited by tumors and undergo differentiation into CAFs during cancer progression to invasive and chemotherapy-resistant stages.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansAnimalsAdipogenesisCarcinomaStem CellsCancer-Associated FibroblastsAdipose TissueNeoplasms

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.